Rib-X℠ is developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. More

5.14.13 - Rib-X Pharmaceuticals Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients with Acute Bacterial Skin and Skin Structure Infections Read More

5.13.13 - Rib-X Pharmaceuticals Appoints John E. Sununu to the Board of Directors Read More

4.03.13 - Rib-X Pharmaceuticals Appoints New Chair of Board of Directors Read More